References
- Abbas FA, Al-Massarany SM, Khan S, Al-Howiriny TA, Mossa JS, Abourashed EA. 2007. Phytochemical and biological studies on Saudi Commiphora opobalsamum L. Nat Prod Res. 21(5):383–391.
- Chang BC, Chen WD, Zhang Y, Yang P, Liu L. 2018. Tripterygium wilfordii mitigates hyperglycemia-induced upregulated Wnt/β-catenin expression and kidney injury in diabetic rats. Exp Ther Med. 15(4):3874–3882.
- Chen FY, Li CJ, Ma J, Ni L, Huang JW, Li L, Lin MB, Hou Q, Zhang DM. 2018. Diterpenoids and lignans from the leaves of Tripterygium wilfordii. Fitoterapia 129:133–137.
- Chen K, Shi QA, Fujioka T, Zhang DC, Hu CQ, Jin JQ, Kilkuskie RE, Lee KH. 1992. Anti-AIDS agents, 4. Tripterifordin, a novel anti-HIV principle from Tripterygium wilfordii: isolation and structural elucidation. J Nat Prod. 55(1):88–92.
- Deeb KSE, Al-Haidari RA, Mossa JS, Ateya AM. 2003. Phytochemical and pharmacological studies of Maytenus forsskaoliana. Saudi Pharm J. 11(4):184–191.
- Fu MM, Zhou XX, Xie DL, Deng FX, Wang HQ. 1994. Study of 2D NMR of two diterpenes from Tripterygium wilfordii Hook. F. Chin J Magnet Resonan. 11(2):165–172.
- Gao C, Wang D, Zhang Y, Huang XX, Song SJ. 2016. Kaurane and abietane diterpenoids from the roots of Tripterygium wilfordii and their cytotoxic evaluation. Bioorg Med Chem Lett. 26(12):2942–2946.
- Guo FJ, Xi ML, Li YC. 1999. Triptotin A and B, two novel diterpenoids from Tripterygium wilfordii. Tetrahedron Lett. 40(5):947–950.
- He L, Peng X, Liu G, Tang C, Liu H, Liu F, Zhou H, Peng Y. 2015. Anti-inflammatory effects of triptolide on IgA nephropathy in rats . Immunopharmacol Immunotoxicol. 37(5):421–427.
- He QL, Titov DV, Li J, Tan M, Ye Z, Zhao Y, Romo D, Liu JO. 2015. Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide. Angew Chem Int Ed Engl. 54(6):1859–1863.
- Kannaiyan R, Shanmugam MK, Sethi G. 2011. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303(1):9–20.
- Li Y, Wang J, Xiao Y, Wang Y, Chen S, Yang Y, Lu A, Zhang S. 2015. A systems pharmacology approach to investigate the mechanisms of action of semen strychni and Tripterygium wilfordii hook F for treatment of rheumatoid arthritis. J Ethnopharmacol. 175:301–314.
- Singh S, Dubey V, Singh DK, Fatima K, Ahmad A, Luqman S. 2017. Antiproliferative and antimicrobial efficacy of the compounds isolated from the roots of Oenothera biennis L. J Pharm Pharmacol. 69(9):1230–1243.
- Sun JY, Yang ZD, Fu GC, Wang YG, Xue HY, Shu ZM. 2017. A new wortmannine derivative from a Tripterygium wilfordii endophytic fungus Talaromyces wortmannii LGT-4. Nat Prod Res. 31(21):2527–2530.
- Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C, Chen Z, Xu Z. 2017. Treatment of rheumatoid arthritis with combination of methotrexate and Tripterygium wilfordii: a meta-analysis. Life Sci. 171:45–50.
- Xiao C, Zhao LH, Liu ZL, Lu C, Zhao N, Yang DJ, Chen SL, Tang JC, Chan A, Lu AP. 2009. The effect of triptolide on CD4+ and CD8+ cells in the Peyer's patch of DA rats with collagen induced arthritis. Nat Prod Res. 23(18):1699–1706.
- Yang GZ, Feng HJ, Li YC. 2001. Di- and triterpenoids from Tripterygium wilfordii. Nat Prod Lett. 15(2):103–110.
- Zhi KK, Yang ZD, Zhou SY, Yao XJ, Li S, Zhang F. 2016. A new furanosteroid from Talaromyces sp. lgt-4, a fungal endophyte isolated from Tripterygium wilfordii. Nat Prod Res. 30(19):2137–2141.
- Zhu WM, Li Y, Gong JF, Zuo LG, Zhang W, Cao L, Gu LL, Guo Z, Li N, Li JS. 2015. Tripterygium wilfordii Hook F. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis. 47(1):14–19.